Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Access and distribution
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Product description Product information

Access and distribution

3 evidence topics · 4 sources

Pre-launch preparation and planned launch timing

“Outlook Therapeutics has initiated pre-launch activities in anticipation of the pending BLA approval.” (opens the source at this quote in a new tab)

“Outlook Therapeutics expects to make LYTENAVA™ available to eligible patients in the United States before year-end. The Company is committed to providing broad patient access support services through comprehensive reimbursement and patient assistance programs designed to help physicians integrate LYTENAVA™ into routine clinical practice for wet AMD.” (opens the source at this quote in a new tab)

Distribution and logistics partner

“As part of the Company's multi-year commercial planning process, Outlook Therapeutics and AmerisourceBergen entered into a strategic commercialization agreement to expand the Company's reach for connecting to retina specialists and their patients. AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as pharmacovigilance services and other services in the United States.” (opens the source at this quote in a new tab)

Reimbursement coding and payer access strategy

“Advancing the U.S. launch strategy for LYTENAVA, including broad market access, reimbursement, pricing, medical affairs, and supply capabilities” (opens the source at this quote in a new tab)
“As part of these efforts, the Company plans to submit an application for a permanent Healthcare Common Procedure Coding System or HCPCS code by October 1, 2026, to support reimbursement following launch.” (opens the source at this quote in a new tab)
“The Company's launch and go-to-market strategy is designed to reflect the evolving biosimilar landscape, affordability considerations, and the potential for additional market entrants, while supporting broad patient access and reimbursement.” (opens the source at this quote in a new tab)
“Our launch strategy reflects a deep understanding of the retina market and the needs of patients, physicians, practices, and payers” (opens the source at this quote in a new tab)
“We are taking a targeted approach to customer engagement, pricing, and reimbursement, while building the commercial and supply capabilities needed to support the introduction of LYTENAVA in the United States.” (opens the source at this quote in a new tab)